Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 9,145 matching trials from the live ClinicalTrials.gov search.

Filters: Rochester, Minnesota Clear all

Conditions: Metastatic Breast Cancer
Interventions: Lasofoxifene and abemaciclib (VERZENIO (R)).; Drug
Lead sponsor: Sermonix Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 16
States / cities: Birmingham, Alabama • Yuma, Arizona • Fountain Valley, California + 12 more

Conditions: Acute Myocardial Infarction
Interventions: AMI Choice Decision Aid, Usual Care; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chronic Subdural Hematoma
Interventions: Minimally Invasive Cortical Access System (MICAS); Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 55 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Breast Carcinoma, Peritoneal Effusion, Recurrent Breast Carcinoma
Interventions: Biospecimen Collection, Medical Chart Review; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 14
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 11 more

Conditions: HIV Infections, Lipodystrophy
Interventions: Pravastatin sodium, Fenofibrate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 57
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 33 more

Conditions: Acne Vulgaris
Interventions: Olumacostat Glasaretil Gel, 5.0%; Drug
Lead sponsor: Dermira, Inc.; Industry
Eligibility: 9 Years and older
Enrollment: 748 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 73
States / cities: Guntersville, Alabama • Glendale, Arizona • Phoenix, Arizona + 63 more

Conditions: Healthy
Interventions: Synaquell(TM), Placebo; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 13 Years to 19 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: irofulven; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 51
States / cities: Little Rock, Arkansas • Duarte, California • La Jolla, California + 41 more

Conditions: Acute Kidney Injury
Interventions: AKI in Care Transitions (ACT) program; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Related Donors Donating PBSC to a Family Member, Healthy Donors, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions: MGTA-145, Plerixafor; Biological
Lead sponsor: Ensoma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Duarte, California • Stanford, California • Atlanta, Georgia + 5 more

Conditions: Endometriosis
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Celiac Disease
Interventions: Simvastatin; Drug
Lead sponsor: Entero Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Bleeding, Blood Loss, Surgical, Cardiovascular Surgical Procedures, Prothrombin Complex Concentrates, Fresh Frozen Plasma
Interventions: Prothrombin complex concentrate (Human), Fresh frozen plasma (FFP); Drug · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Childhood Alveolar Soft Part Sarcoma, Childhood Angiosarcoma, Childhood Epithelioid Sarcoma, Childhood Fibrosarcoma, Childhood Gliosarcoma, Childhood Leiomyosarcoma, Childhood Liposarcoma, Childhood Malignant Peripheral Nerve Sheath Tumor, Childhood Synovial Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Osteosarcoma, Rhabdomyosarcoma
Interventions: Cixutumumab, Laboratory Biomarker Analysis, Temsirolimus; Biological · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 30 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 74
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 62 more

Conditions: End Stage Renal Disease, Transplantation
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 7,029 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota

Conditions: Mycobacterium Avium Complex, Nontuberculous Mycobacterium Infection
Interventions: Azithromycin, Ethambutol, Rifampin; Drug
Lead sponsor: Kevin Winthrop; Other
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 25
States / cities: Loma Linda, California • San Diego, California • San Francisco, California + 21 more

Conditions: Kidney Transplantation
Interventions: MRI 1.5T and 3.0T; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Amyloidosis
Interventions: Belantamab mafodotin, Cyclophosphamide, Bortezomib, Dexamethasone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 8
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 5 more

Conditions: Psoriasis
Interventions: Alefacept exposure; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 1,897 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 241
States / cities: Birmingham, Alabama • Fairhope, Alabama • Gadsden, Alabama + 206 more

Conditions: Obesity
Interventions: Transcutaneous electrical nerve stimulation (TENS); Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
Interventions: Tovorafenib, Chemotherapeutic Agent; Drug
Lead sponsor: Day One Biopharmaceuticals, Inc.; Industry
Eligibility: Up to 25 Years
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 38
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: clarithromycin, prasterone; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Carcinoma
Interventions: Osimertinib, Savolitinib, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 11
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 8 more

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Nicole Hamblett; Other
Eligibility: 12 Years and older
Enrollment: 987 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 80
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more

Search by objective public record fields.

Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Wiser Choices in Acute Myocardial Infarction

A Study to Evaluate Endoscope-assisted, Minimally-invasive Cortical Access System for Chronic Subdural Evacuation

Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer

Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids

A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

The Effect of Synaquell™ in Contact Sport Athletes

Irofulven in Treating Children With Recurrent or Refractory Solid Tumors

A Study of Acute Kidney Injury in Care Transitions

MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies

Recovery and Symptom Relief Following Percutaneous Ablation of Abdominal Wall Endometriosis

Simvastatin Metabolism as a Test for CD Activity (IRB 15-007568]

PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding

Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma

Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study

Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease

Noninvasive Evaluation of Renal Allograft Fibrosis by MRI

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

Assessment and Tracking of Long-term Alefacept Safety

Dermatome Electrical Stimulation on Individuals With Overweight and Class I Obesity

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy